Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses

Diagnostic Pathology

Volumn 4, Issue 1, 2009, Pages

  Völker, Hans Ullrich ^a   Scheich, Matthias ^a   Berndt, Annette ^a   Haubitz, Imme ^a   Metzger, Alexandra ^a   Müller Hermelink, Hans Konrad ^a   Kämmerer, Ulrike ^a   Schmidt, Melanie ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68149141467     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-4-18     Document Type: Article

References (23)

1. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. RH Spiro AG Huvos EW Strong, Am J Surg 1974 128 512 520 10.1016/0002-9610(74)90265-7 4371368
2. Adenoid cystic carcinoma of the head and neck. S Chummun NR McLean CG Kelly PJ Dawes D Meikle S Fellows JV Soames, Br J Plast Surg 2001 54 476 480 10.1054/bjps.2001.3636 11513507
3. Adenoid cystic carcinoma of the head and neck: a review. PJ Bradley, Curr Opin Otolaryngol Head Neck Surg 2004 12 127 132 10.1097/00020840-200404000- 00013 15167050
4. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. RL Dodd NJ Slevin, Oral Oncol 2006 42 759 769 10.1016/j.oraloncology.2006.01.001 16757203
5. Salivary gland cancers: current treatments, molecular characteristics and new therapies. SR Chandana BA Conley, Expert Rev Anticancer Ther 2008 8 645 652 10.1586/14737140.8.4.645 18402531
6. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. MR Pfeffer Y Talmi R Catane Z Symon A Yosepovitch M Levitt, Oral Oncol 2007 43 33 36 10.1016/j.oraloncology.2005.12.026 16757202
7. Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas. HU Volker M Scheich B Schmausser U Kammerer M Eck, Eur Arch Otorhinolaryngol 2007 264 1431 1436 10.1007/s00405-007-0394-x 17639446
8. Expression of transketolase-like 1 and activation of Akt in grade IV glioblastomas compared with grades II and III astrocytic gliomas. HU Volker C Hagemann J Coy R Wittig S Sommer J Stojic I Haubitz GH Vince U Kammerer CM Monoranu, Am J Clin Pathol 2008 130 50 57 10.1309/6H9844AMMET82DBJ 18550470
9. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. M Schmidt U Kammerer S Segerer A Cramer N Kohrenhagen J Dietl HU Voelker, Eur J Obstet Gynecol Reprod Biol 2008 139 72 78 10.1016/j.ejogrb.2008.02.009 18394773
10. Expression of transketolase-like 1 (TKTL1) and p-Akt correlates with the progression of cervical neoplasia. N Kohrenhagen HU Voelker M Schmidt M Kapp M Krockenberger T Frambach J Dietl U Kammerer, J Obstet Gynaecol Res 2008 34 293 300 10.1111/j.1447-0756.2008.00749.x 18686341
11. Akt stimulates aerobic glycolysis in cancer cells. RL Elstrom DE Bauer M Buzzai R Karnauskas MH Harris DR Plas H Zhuang RM Cinalli A Alavi CM Rudin CB Thompson, Cancer Res 2004 64 3892 3899 10.1158/0008-5472.CAN-03-2904 15172999
12. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma. GM Oremek S Teigelkamp W Kramer E Eigenbrodt KH Usadel, Anticancer Res 1999 19 2599 2601 10470201
13. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. M Kunkel TE Reichert P Benz HA Lehr JH Jeong S Wieand P Bartenstein W Wagner TL Whiteside, Cancer 2003 97 1015 1024 10.1002/cncr.11159 12569601
14. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Y Kato K Tsuta K Seki AM Maeshima S Watanabe K Suzuki H Asamura R Tsuchiya Y Matsuno, Mod Pathol 2007 20 215 220 10.1038/modpathol.3800732 17192790
15. Diagnostic value of GLUT-1 immunoreactivity to distinguish benign from malignant cystic squamous lesions of the head and neck in fine-needle aspiration biopsy material. MF Weiner RN Miranda RH Bardales P Mukunyadzi SJ Baker S Korourian LE De Las Casas, Diagn Cytopathol 2004 31 294 299 10.1002/dc.20127 15468132
16. ber den Stoffwechsel der Carcinomzelle. O Warburg K Posener E Negelein, Biochem Z 1924 152 309 344
17. Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. JF Coy D Dressler J Wilde P Schubert, Clin Lab 2005 51 257 273 15991799
18. The Akt/protein kinase B-dependent anti-apoptotic pathway and the mitogen-activated protein kinase cascade are alternatively activated in human glioblastoma multiforme. J Schlegel G Piontek B Budde F Neff A Kraus, Cancer Lett 2000 158 103 108 10.1016/S0304-3835(00)00515-2 10940516
19. Epiregulin promotes migration and invasion of salivary adenoid cystic carcinoma cell line SACC-83 through activation of ERK and Akt. K Hu SL Li YH Gan CY Wang GY Yu, Oral Oncol 2009 45 156 163 10.1016/j.oraloncology.2008.04.009 18620900
20. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. CV Dang BC Lewis C Dolde G Dang H Shim, J Bioenerg Biomembr 1997 29 345 354 10.1023/A:1022446730452 9387095
21. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. R Airley J Loncaster S Davidson M Bromley S Roberts A Patterson R Hunter I Stratford C West, Clin Cancer Res 2001 7 928 934 11309343
22. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. TA Yap MD Garrett MI Walton F Raynaud JS de Bono P Workman, Curr Opin Pharmacol 2008 8 393 412 10.1016/j.coph.2008.08.004 18721898
23. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. D Koul R Shen S Bergh Y Lu JF de Groot TJ Liu GB Mills WK Yung, Mol Cancer Ther 2005 4 1681 1688 10.1158/1535-7163.MCT-05-0258 16275989